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postmarketing, multicentre, pharmacokinetic study
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AbstrACt
background Women with chronic inflammatory 
diseases face uncertainty regarding the safety of 
biologics during breast feeding. CrAdLE was the first 
industry-sponsored study to evaluate certolizumab pegol 
(CZp) concentrations in human breast milk and estimate 
average daily infant dose (AdId) of maternal CZp.
Methods CrAdLE (nCt02154425) was a 
pharmacokinetic study of lactating mothers receiving 
CZp. After ≥3 CZp doses, breast milk samples were 
collected across one dosing period (14 days for 200 mg 
every 2 weeks [Q2W]; 28 days for 400 mg every 4 weeks 
[Q4W]). optimal analytical methods were developed to 
determine CZp and polyethylene glycol (pEG) levels in 
breast milk. AdId and relative infant dose (rId) were 
estimated. Safety events in mothers and infants were 
assessed.
results 19 CZp-treated mothers were screened; 17 
entered the sampling period: 16 on 200 mg Q2W, 1 on 
400 mg Q4W. 77/137 (56%) breast milk samples had 
no measurable CZp. For 4/17 mothers, all samples were 
below the lower limit of quantification (LLoQ). Estimated 
AdId was 0–0.0104 mg/kg/day; median rId: 0.15%. 
pEG was undetectable in 134/137 samples (results could 
not be determined in three samples). Infants of CZp-
exposed mothers had a safety profile consistent with that 
of unexposed similar-age infants.
Conclusion When quantifiable, CZp concentrations 
were <3× LLoQ (<1% plasma concentration observed 
with therapeutic dose), indicating no/minimal CZp 
transfer from plasma to breast milk. rId was 0.15% 
of maternal dose; <10% is considered unlikely to be 
of clinical concern. no pEG transfer was observed. CZp 
absorption by infants via breast milk is unlikely due to its 
low oral bioavailability and Fc- free molecular structure. 
these findings are reassuring and support continuation 
of CZp treatment during breast feeding.
trial registration number nCt02154425; results.
IntroduCtIon
Women with chronic inflammatory diseases, such 
as rheumatoid arthritis (RA), ankylosing spondy-
litis (AS), axial spondyloarthritis (axSpA), psori-
atic arthritis (PsA), and Crohn’s disease (CD) often 
experience postpartum flares.1–4 Treatment of 
these conditions frequently involves monoclonal 
antibodies, such as anti-tumour necrosis factor 
(anti-TNF), and diffusion of these molecules into 
breast milk has been reported.5 6 Existing evidence 
on anti-TNF transfer into breast milk lacks robust 
and systematic sample collection and assays vali-
dated in breast milk; reports are restricted to a few 
studies with a limited number of patients receiving 
infliximab,7 adalimumab,7 8 etanercept9 or certoli-
zumab pegol (CZP).10 11 The lack of systematic 
collection of breast milk samples throughout dosing 
intervals, coupled with the absence of drug-spe-
cific assays validated in breast milk, suggests that 
existing data cannot be confidently translated into 
evidence-based clinical practice. Consequently, 
women treated with monoclonal antibodies who 
are considering breast feeding, as well as their 
physicians, face uncertainty regarding drug safety.12
Breast feeding is extremely important to child 
health and development.13 14 Immunological and 
anti-inflammatory agents are passed on to the infant 
via breast milk, allowing development of protective 
mechanisms against several diseases.15 In addition 
to creating an emotional bond between mother and 
child at an early stage, breast feeding has been asso-
ciated with a decreased risk for sudden infant death 
syndrome16 and other conditions.17 Despite these 
benefits, the conflict between the risks of maternal 
medications needed for postpartum disease flare 
and ensuring optimal child nutrition through 
breast feeding presents a complex challenge.
Although biologics generally have very low 
oral bioavailability due to their large molecular 
size and the proteolytic environment in the diges-
tive system,18 the neonatal Fc receptor on human 
intestinal epithelial cells may promote uptake of 
undigested immunoglobulins (IgGs). CZP, the only 
PEGylated anti-TNF without an Fc region, has 
demonstrated efficacy for the treatment of RA,19 
CD,20 axSpA21 and PsA.22 Physiologically, only 
minimal amounts of CZP are likely to cross into 
breast milk and be absorbed by the infant, due to its 
large molecule size and the replacement of the Fc 
portion with polyethylene glycol (PEG).23
The primary aim of CRADLE (NCT02154425), 
the first industry-sponsored, multicentre study to 
evaluate transfer of a biologic into breast milk, was 
to determine the concentrations of CZP in mature 
breast milk and to calculate the average daily infant 
dose (ADID), which is the daily CZP dose poten-
tially ingested by the infant. Including multiple 
predefined sampling time points throughout the 
dosing interval allowed full characterisation of the 
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CZP pharmacokinetics (PK) in mature milk at steady state. The 
exploratory aim was to determine the breast milk concentrations 
of PEG. The relative infant dose (RID), which estimates the 
theoretical infant dose as a percentage of the weight-normalised 
maternal dose was calculated post hoc. Safety events in mothers 
and infants were examined.
MetHods
study design and patients
CRADLE (NCT02154425) was a prospective, postmarketing, 
multicentre PK study to measure the CZP concentration in 
breast milk. It enrolled lactating mothers, at least 6 weeks post-
partum with no upper age limit for infants, receiving commercial 
CZP for an approved indication (RA, CD, AS/axSpA and PsA), as 
prescribed by their treating physician. Importantly, the decision 
to treat with CZP and to breastfeed were made prior to and 
independently from study participation. CZP was not provided 
by the study sponsor.
No exclusions were made regarding multiple births, but 
women who were pregnant, or planned to become pregnant 
during study duration, were ineligible to participate. Mothers 
with positive or indeterminate tuberculosis (TB) testing, active 
or latent TB infection or at high risk of TB infection were 
excluded, as were mothers who had received treatment with 
any biologic or anti-TNF other than CZP within five half-lives 
prior to collection of the first milk sample. Also excluded were 
mothers of premature infants (<37 weeks gestation). Mothers 
were withdrawn if they took any biological disease-modifying 
drug other than CZP during the sampling period. In addition, 
mothers with active mastitis were excluded from the sampling 
period until resolution.
The study was designed as a ‘milk-only’ study in accordance 
with the 2005 US Food and Drug Administration (FDA) draft 
guidance24 and was conducted between September 2014 and 
October 2015 by six investigators: three in the USA, one in 
Switzerland and two in the Netherlands. In addition to tradi-
tional site-based enrolment, an open enrolment model was used 
in the USA and Canada, with remote oversight by a participating 
investigator. This enabled remotely located mothers to take part 
in the study without the burden of travel, thus allowing the 
study to reach more mothers meeting enrolment criteria than 
through traditional site-based enrolment alone. The study design 
and protocol were approved by the local ethics committee or 
institutional review board (IRB) at each participating site, or 
by a central IRB, as applicable. All mothers provided written 
informed consent to participate.
study procedures
Mothers received commercial CZP on either the 2-weekly 
dose (CZP 200 mg every 2 weeks [Q2W]) or the 4-weekly dose 
regimen (CZP 400 mg every 4 weeks [Q4W]). After at least three 
CZP doses, when plasma CZP concentration in the mothers was 
considered at steady-state, mature breast milk samples were 
collected across a single dosing period. For mothers on CZP 
200 mg Q2W, samples were collected on days 0, 2, 4, 6, 8, 10, 12 
and 14; for mothers on CZP 400 mg Q4W, an additional sample 
was collected on day 28 (figure 1). All mothers were to dose on 
the same day as the first sample collection, with date and time 
of dosing being recorded by the home healthcare nurse. Predose 
samples were those collected on days 0 and 14 for mothers on 
CZP 200 mg Q2W, and on days 0 and 28 for mothers on CZP 
400 mg Q4W. Compliance with CZP therapy was not mandated 
in the study; however, at day 0, all mothers were confirmed to 
have received at least three doses of CZP prior to the beginning 
of the sampling period.
 In-home nursing visits for milk sample collection minimised 
the burden on mothers and were carried out at all study sites, 
using the same procedure: at each visit and at approximately 
the same time of day, milk was pumped from both breasts until 
completely emptied (accommodating the mothers’ schedule), 
using the electronic breast pump (Medela Advanced Personal 
Double Pump) provided by the sponsor. Milk from both breasts 
was mixed by the home healthcare nurse, before 5 mL were 
placed on dry ice and shipped to the central laboratory (Quintiles; 
Atlanta [USA sites] or Edinburgh, UK [European sites]). During 
each visit, the nurse confirmed whether the infant had received 
any other nutrition in the prior 2 days to explore whether there 
was any difference between women who breast fed exclusively 
and those that supplemented breast feeding with other nutrition 
sources (eg, formula milk). To avoid interference by PEG-con-
taining creams, mothers were only permitted to use PEG-free 
nipple/breast creams provided by the sponsor.
Figure 1 CRADLE study design. CZP, certolizumab pegol; Q2W, every 2 weeks; Q4W, every 4 weeks.
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Samples were subsequently analysed at Covance Inc. (Chan-
tilly, Virginia, USA). CZP concentration in breast milk was 
measured using an electro-chemiluminescence immunoassay, 
in which CZP was captured by a TNF-coated multiarray elec-
trode and detected with an anti-PEG antibody, prior to reading 
on a Meso Scale Discovery (MSD; Rockville, Maryland, USA) 
platform.25 The assay is CZP-specific and, due to the technical 
advantages of the MSD methodology (high sensitivity, large 
dynamic range, small sample volume26 27), >10 times more sensi-
tive (lower limit of quantification [LLOQ]: 0.032 µg/mL) than 
the previous ELISA used in other CZP PK studies.11 28 29 The 
assay was validated in milk; CZP stability in milk was confirmed.
The concentrations of total PEG (ie, PEG present as intact 
CZP or in deconjugated form) were determined by a validated 
assay using nuclear magnetic resonance spectroscopy (LLOQ: 
0.5 µg/mL).30
study endpoints
The primary objectives were to determine CZP concentrations 
in breast milk and to calculate the ADID of maternal CZP. 
The exploratory objective was to assess the concentration of 
total PEG in breast milk. A post hoc variable, RID, was calcu-
lated.31 RID is the infant dose as a per cent of the weight-related 
maternal dose and is widely used by lactation specialists, paedia-
tricians and neonatologists to assess risk to infants.31 32 Analysis 
of the PK parameters was performed using Phoenix WinNonlin 
V.6.4 (Certara, USA).
The safety analysis included adverse events (AEs) in all 
mothers who received at least one dose of CZP and the infants 
of all participating mothers from the time of informed consent 
through safety follow-up (up to 5 weeks±5 days after the 
final sample was obtained). Patient consent was obtained after 
delivery, up to 10 weeks before day 0. Prior to sampling on day 0, 
eligibility was reconfirmed. During each sampling visit, patients 
were given the opportunity to report AEs spontaneously, and a 
general prompt using open-ended questions was also given. If an 
AE was reported during the in-home visit, the home healthcare 
nurse contacted the principal investigator to speak directly with 
the patient for further assessment.
AEs of interest included any opportunistic infections, malig-
nancies (including unspecified), major adverse cardiac events, 
haematopoietic cytopaenias, serious bleeding, hepatic events and 
injection reactions (local or systemic).32 AEs were coded using 
MedDRA V.18.1.
statistical analysis
No formal sample size calculations were performed, as no statis-
tical hypotheses were being tested. The planned sample size for 
the study was 16 mothers; approximately twice the minimum 
number of subjects considered sufficient by the FDA for a ‘milk-
only’ study.24 Summary statistics were reported for quantitative 
variables and frequency tables for qualitative data. Statistical 
analysis was performed using SAS V.9.3. All summaries of PK 
variables were based on the values observed at each visit: no 
imputation was used.
In addition to CZP concentrations, three measures of CZP 
transfer were considered: (1) the average daily CZP concentra-
tion in breast milk (Cave), (2) ADID and (3) RID. Cave is calcu-
lated by non-compartmental analysis from the concentration 
versus time profile over the dosing interval, using the actual 
sampling days. ADID is the dose of CZP ingested by a child 
based on Cave and the estimated daily volume of milk ingested. 
As per the 2005 FDA draft guidance,24 the standardised milk 
consumption of a fully breastfed 2-month-old infant (150 mL/
kg/day) was used to calculate the ADID over a dosing interval 
(14 or 28 days) from the study data:
 
Estimated ADID
(
mg/kg/day
)
= Caverage × 150mL/kg/day 
The exploratory post hoc variable, RID, was calculated as 
follows31:
 RID
(
%
)
=
ADID
(
mg/kg/day
)
Maternal dose
(
mg/kg/day
) × 100 
RID was not calculated when all results were below the lower 
limit of quantification (BLQ), as was the case in four mothers.
Subgroup analyses were performed, based on the mothers’ 
indications (RA, CD and PsA) and on the use of supplemental 
nutrition (non-exclusive vs exclusive breast feeding) for the PK 
parameters. Subgroup analyses were not performed on groups 
with fewer than three patients (axSpA).
results
Patients
Between 8 September 2014 and 30 October 2015, 19 mothers 
were screened; 18 received commercial CZP and met the 
inclusion criteria (one mother was prescribed CZP prior to 
screening, but did not receive CZP and was therefore ineli-
gible). One mother failed screening and discontinued the study 
due to an AE of herpes zoster. All 17 mothers who entered 
the sampling period completed the study (no missed visits); 
table 1 Demographics and baseline characteristics of mothers and 
infants
All mothers (n=18)*
Mean (sd), unless otherwise stated
  Age, years 33.7 (4.2)
  Weight, kg 68.9 (9.6)†
  BMI, kg/m² 23.6 (3.0)†
Location, n
  USA/Canada‡ 10
  Switzerland 5
  The Netherlands 3
Mother’s indication for CZP treatment, n†
  Rheumatoid arthritis 7
  Crohn’s disease 5
  Psoriatic arthritis 3
  Axial spondyloarthritis/ankylosing spondylitis 2
All infants (n=17)
Median (min–max), unless otherwise stated
  Female, n (%) 11 (64.7)
  Gestational age at birth, weeks 40.0 (39.0–41.7)
  Weight at birth, kg 3.5 (2.6–4.1)
  Length at birth, cm 50.7 (48.0–57.0)
  Age at time of mother’s first sample, months 2.8 (1.6–16.8)
  Age at time of mother’s first sample, n (%)
  ≤6 months 13 (76.5)
  >6 months–≤12 months 2 (11.8)
  ≥12 months–≤18 months 2 (11.8)
*Includes one screen failure.
†n=17.
‡One Canadian patient enrolled under the central USA site, which was approved by 
the Canadian central IRB.
BMI, body mass index; IRB, institutional review board.
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100% of planned samples were collected. Seven mothers 
(38.9%) were diagnosed with RA, 5 (27.8%) with CD (two of 
which also had rheumatic diseases), 3 (16.7%) with PsA and 
2 (11.1%) with axSpA. The demographics and baseline char-
acteristics of all mothers screened and of all infants of partici-
pating mothers are shown in table 1. The mothers’ indications 
for CZP treatment and their infants’ age at the time of first 
sampling are listed in online supplementary table 1.
Pharmacokinetic results
One hundred thirty-seven breast milk samples were collected 
from 17 mothers (16 on CZP 200 mg Q2W, one on CZP 
400 mg Q4W). All samples had CZP concentrations that were 
minimal or BLQ. Importantly, 77/137 (56%) samples had no 
measurable CZP (table 2). Four of the 17 women, including 
one on CZP 400 mg Q4W, did not have measurable CZP levels 
in their breast milk at any time point. In the remaining 13 
mothers with a measurable concentration during at least one 
time point, the highest CZP concentration was 0.076 µg/mL, 
less than three times LLOQ (0.032 µg/mL).
The estimated ADID ranged from 0 to 0.0104 mg/kg/day; median 
estimated ADID was 0.003503 mg/kg/day (table 3). Additional 
CZP PK parameters are shown in table 3. The RID, calculated post 
hoc,31 32 ranged from 0.04% to 0.30%; median RID was 0.15%.
PK parameters were similar for women with different indica-
tions as well as between mothers using supplemental nutrition 
and those breast feeding exclusively.
table 2 Concentrations of CZP (μg/mL) in breast milk after administration of CZP dose in mothers
Mother 
number
relative time (days)
0 2 4 6 8 10 12 14 28
17 BLQ BLQ BLQ BLQ BLQ BLQ BLQ BLQ BLQ
4 BLQ BLQ BLQ BLQ BLQ BLQ BLQ BLQ –
13 BLQ BLQ BLQ BLQ BLQ BLQ BLQ BLQ –
14 BLQ BLQ BLQ BLQ BLQ BLQ BLQ BLQ –
7 BLQ BLQ BLQ BLQ BLQ 0.035 BLQ BLQ –
6 BLQ BLQ 0.044 0.048 BLQ BLQ BLQ BLQ –
8 BLQ BLQ 0.035 0.034 0.043 BLQ BLQ BLQ –
10 BLQ BLQ BLQ 0.033 0.042 0.042 BLQ BLQ –
12 BLQ BLQ 0.034 0.037 0.033 BLQ BLQ BLQ –
2 BLQ BLQ 0.035 0.037 0.041 BLQ 0.043 BLQ –
11 BLQ BLQ 0.051 0.038 0.042 BLQ 0.033 BLQ –
15 BLQ BLQ 0.041 0.034 0.033 BLQ 0.037 BLQ –
16 0.040 0.033 0.036 0.037 0.043 BLQ BLQ BLQ –
3 BLQ 0.032 0.049 0.053 0.037 0.037 0.033 0.033 –
9 0.039 0.040 0.047 0.045 0.042 0.043 0.038 0.035 –
1 0.057 0.051 0.066 0.065 0.062 0.056 0.052 0.041 –
5 0.056 0.069 0.074 0.076 0.076 0.069 0.069 0.060 –
White coloured areas depict CZP concentration Less than 3×LLOQ (<0.096 μg/mL).
Grey coloured areas depict CZP concentration Less than 2×LLOQ (<0.064 μg/mL).
Dark grey coloured areas depict CZP concentration BLQ (<0.032 μg/mL).
Days 0 and 14 are predose for mothers on the CZP 200 mg Q2W dosing regimen.
Days 0 and 28 are predose for the mother on the CZP 400 mg Q4W dosing regimen.
For reference, the mean 12-week CZP plasma Ctrough value, that is, the trough concentration at steady-state, reported from non-pregnant patients with RA receiving CZP 200 mg 
Q2W in the RAPID2 trial was 15.7 µg/mL (95% CI 14.0 to 17.7).28
BLQ, below the lower limit of quantification, <0.032 µg/mL; CZP, certolizumab pegol; LLOQ, lower limit of quantification; Q2W, every 2 weeks; Q4W, every 4 weeks; RA, 
rheumatoid arthritis.
table 3 Pharmacokinetic parameters of CZP in breast milk after administration of CZP
Parameter n Geo. mean (Geo. CV (%))
Median
(min–max)
All mothers: both CZP 200 mg Q2W and CZP 400 mg Q4W dosing regimens
  Estimated average daily infant dose (mg/kg/day) 17 0.00426 (59.4) 0.003503
(0–0.0104)
  Cave (μg/mL) 17 0.0248 (58.0) 0.02335
(0.00744–0.0693)
  tmax (day) 13 – 5.051
(2.89–11.9)
Mothers on CZP 200 mg Q2W dosing regimen only
  AUCT (day* μg/mL) 13 0.398 (59.4) 0.4249
(0.104–0.970)
  Cmax (μg/mL) 16 0.0383 (50.3) 0.04285
(BLQ–0.0758)
AUCT, area under the curve over a dosing interval (14 or 28 days); Cave, average concentration over a dosing interval;  Cmax, maximum observed CZP concentration in milk over 
the dosing interval; CV, coefficient of variations; CZP, certolizumab pegol; Geo.: geometric; Q2W, every 2 weeks; Q4W, every 4 weeks; tmax, time of the maximum observed 
concentration.
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PEG concentration was analysed in 137 samples; 134 samples 
had no quantifiable PEG; three samples were classed as not 
reportable (online supplementary table 2).
safety
The safety analysis included 18 CZP-exposed mothers and 17 
infants. AEs are shown in table 4. One mother discontinued the 
study during the screening period due to an AE of herpes zoster. 
Overall, 10 mothers (55.6%) experienced 14 AEs, and 8 infants 
(47.1%) experienced 11 AEs.
AEs in mothers and infants were mostly mild to moderate 
in intensity (mothers: three mild [16.7%] and six moderate 
[33.3%]; infants: six mild [35.3%] and two moderate [11.8%]). 
One severe AE (5.6%) was reported in one mother: a breast 
abscess, which occurred during the screening period and was 
resolved prior to sampling. Five AEs in four mothers were 
classified as drug-related: two (11.1%) upper respiratory tract 
infections, and one each (5.6%) of herpes zoster, CD flare and 
pneumonia. Nasopharyngitis in one infant (5.9%) was consid-
ered mild in intensity and classified as drug-related by the prin-
cipal investigator, based on the known CZP safety profile.33 No 
serious AEs were reported in the infants. Overall, events in the 
mothers were consistent with the known CZP safety profile, 
and the events observed in infants were consistent with those in 
unexposed infants of similar age.34–36
dIsCussIon
CRADLE was the first industry-sponsored clinical lactation 
study evaluating the transfer of a biologic into mature breast 
milk of women with chronic inflammatory diseases. Because low 
levels of IgGs have been shown to diffuse into breast milk,5 it 
is important to measure the relative abundance of therapeutic 
antibodies in breast milk.32 This study found minimal transfer 
of CZP into breast milk, with an infant receiving, on average, 
0.15% (RID) of the maternal dose.
While prior studies entailed case reports with few milk 
samples obtained at varying times after dosing,37 38 CRADLE was 
designed to fully characterise the CZP PK profile in mature milk 
at steady-state. Following the FDA recommendation and in line 
with the 2005 guidance for industry,24 the study was designed 
as a ‘milk-only’ study. The rationale was that the CZP PK 
profile was already well established28 and that lactation was not 
expected to substantially change its PK. In addition, this ‘milk-
only’ study design avoided additional burden on mothers and 
their babies: milk sampling did not occur earlier than 4–6 weeks 
postpartum to ensure that lactation and feeding patterns were 
well established, mature milk was being produced and maternal 
physiology had largely returned to pre-pregnancy state.
CZP concentration was BLQ in 56% of milk samples. When 
measurable, CZP concentrations were less than 3× LLOQ, with 
a marginal maximum concentration (0.0758 µg/mL). This is 
equivalent to less than 1% of the expected mean CZP plasma 
table 4 Adverse events (AEs) occurring in mother-infant pairs
Mothers Infants
Mother (n=18)* no. of Aes in mother (n) Ae Infant (n=17)* no. of Aes in infant (n) Ae
1 None 1 2 Lichen striatus
Upper respiratory tract 
infection
2 1 breast abscess‡  2 None
3 None 3 1 Gastro-oesophageal reflux 
disease
5 1 Rash 5 1 Nasopharyngitis
7 1 Upper respiratory tract infection 7 1 Upper respiratory tract 
infection
8 2 Candida infection 8 1 Candida infection
Crohn’s disease flare
10 1 Viral upper respiratory tract infection 10 None
11 1 Headache 11 None
13 1 Psoriatic arthritis flare 13 None
14 2 Nipple disorder 14 2 Vomiting
Headache Nasopharyngitis
15 None 15 1 Nasopharyngitis
16 2 Upper respiratory tract infection 16 2 Upper respiratory tract 
infection
Pneumonia Nasopharyngitis
SF† 2 Herpes zoster N/A
Galactostasis
Total number of mothers experiencing any AE 10 Total number of infants experiencing any AE 8
Total number of AEs 14 Total number of AEs 11
The safety analysis included all mothers who received at least one dose of CZP and the infants of all mothers who participated in the study. The safety follow-up period extended 
up to 5 weeks (±5 days) after the final sample was collected. AEs in mother-infant pairs were not necessarily associated temporally.
Bold text indicates serious adverse event (SAE).
*Mother-infant pairs are numbered as per table 2.
†SF, screen failure: mother discontinued from study due to AE of herpes zoster during screening period.
‡Breast abscess during screening period, which resolved prior to sampling.
CZP, certolizumab pegol; N/A, not applicable as the mother did not enter the sampling period.
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trough concentration for a CZP-treated adult,28 39 indicating 
no to minimal transfer of CZP from plasma to breast milk. No 
transfer of total PEG from plasma to breast milk was observed.
The estimated daily dose of CZP ingested by breastfed infants 
over the dosing interval was minimal, with maximum ADID 
of 0.0104 mg/kg/day. The median CZP RID was 0.15%. The 
number of medications available to breast feeding mothers 
requiring drug therapy is increasing, and RID is a useful param-
eter for assessing drug safety in breastfeeding by providing a 
standardised means of referencing infant to maternal exposure 
on a dose/weight basis.31 An RID <10% is considered safe by 
lactation specialists, with the estimate evaluated against the 
potential toxicity of the drug.31 32 40 Examples of drugs consid-
ered safe when breast feeding include analgesics (ibuprofen and 
acetaminophen), antibiotics (penicillins and cephalosporins), 
antidepressants (citalopram and sertraline) and anticoagulants 
(heparin and dalteparin) (RID <10%).40
Subgroup analyses suggest that transfer of CZP into 
breast milk is independent of the mother’s indication and 
CZP dosing regimen. Additionally, no difference between 
subgroups was observed regarding CZP transfer into milk of 
exclusively breastfeeding mothers versus those who supple-
mented nutrition.
Although there were no enrolment restrictions for patient 
numbers for the two dosing regimens, 16/17 patients were on 
the single dose regimen, as per physician discretion. To our 
knowledge, this does not impact the results’ relevance.
Enrolment for studies of this nature is challenging, given 
the unique barriers to participation, such as ethical, legal and 
medical considerations associated with this sensitive patient 
population. The CRADLE open enrolment, combined with the 
traditional site-based model, and including in-home nursing 
services, allowed mothers to participate without the burden of 
travel. This operational model was essential to the successful 
completion of the study.
We acknowledge that no preterm babies were included in this 
study, although it is well known that prematurity is an under-
lying risk for women with inflammatory diseases, particularly 
those with high disease activity.41 It is noteworthy that while 
valuable data might be obtained from studying drug absorp-
tion in premature babies, due to the possible differences in their 
digestive tracts from full-term infants,42 such an analysis would 
have been outside the scope of this study.
Similarly, milk collection from mothers immediately after birth 
was not included for a number of reasons: due to the very limited 
volume of breast milk/colostrum available at this time, obtaining 
these samples would be challenging and, in addition, the study 
did not wish to disrupt the initial mother/infant bonding. These 
limitations raise awareness for the need of further research into 
drug transfer from mother to infant.
No new CZP safety issues were identified. AEs in mothers 
were consistent with the current CZP safety profile, while 
events in infants were consistent with those occurring in unex-
posed infants of similar age. For reference, incidence for minor 
infections in infants is 6–8 times per year for upper respira-
tory tract infection/nasopharyingitis34 35 and 2%–5% for oral 
candidiasis.36
In conclusion, these findings suggest that the level of CZP 
ingested by the suckling infant is minimal and indicate that 
continuation of CZP treatment is compatible with breast feeding. 
The robust clinical evidence from the CRADLE study allows 
breastfeeding women with chronic inflammatory diseases and 
their treating physicians to make informed decisions regarding 
their postpartum treatment.
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